Rejoni

About Rejoni

Rejoni, Inc. is a privately held medical technology company established in June 2020 by serial entrepreneur Amar Sawhney, who serves as the CEO. Based in Bedford, Massachusetts, the firm is focused on designing and developing proprietary hydrogel-based products to address unmet needs in women's health and gynecological surgery. The company's business model revolves around the development and commercialization of these medical devices.

Rejoni's initial focus is on preventing intrauterine adhesions (IUAs), or scar tissue, which can form after gynecological procedures and lead to complications like infertility and abnormal bleeding. Up to 40% of women who undergo surgical procedures inside the uterus develop IUAs, a condition for which there is currently no FDA-approved treatment. The company's lead product is the Juveena™ Hydrogel System, a temporary implant designed to prevent the formation of these adhesions. This system involves a proprietary transcervical catheter that delivers two liquid precursors into the uterine cavity. These liquids then form a soft, absorbable hydrogel that is over 90% water, separating the uterine walls during the critical healing period before naturally dissolving within a few weeks.

The company has secured significant funding to advance its clinical trials and product pipeline. A Series A funding round in September 2020 raised $15 million, led by Ascension Ventures. This was followed by a $25 million Series B round in December 2022, led by Catalyst Health Ventures, with continued support from investors like Ascension Health Ventures, Delos Capital, and Sparta Group. These funds are allocated to completing a landmark IDE pivotal study for the Juveena™ system in the United States and exploring additional therapeutic applications. A major milestone was reached in early 2025 with the completion of patient enrollment in the Juveena pivotal clinical study, moving the product closer to potential FDA submission.